Windtree Therapeutics Inc - Asset Resilience Ratio
Windtree Therapeutics Inc (WINT) has an Asset Resilience Ratio of 0.00% as of December 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1996–2019)
This chart shows how Windtree Therapeutics Inc's Asset Resilience Ratio has changed over time. Check Windtree Therapeutics Inc (WINT) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Windtree Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see WINT company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Windtree Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Windtree Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Windtree Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Windtree Therapeutics Inc (1996–2019)
The table below shows the annual Asset Resilience Ratio data for Windtree Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 0.00% | $0.00 | $118.97 Million | -- |
| 2018-12-31 | 11.69% | $13.96 Million | $119.40 Million | +5.46pp |
| 2008-12-31 | 6.23% | $2.05 Million | $32.89 Million | -19.40pp |
| 2007-12-31 | 25.62% | $16.08 Million | $62.74 Million | +23.21pp |
| 2006-12-31 | 2.41% | $829.00K | $34.40 Million | -3.39pp |
| 2005-12-31 | 5.80% | $3.25 Million | $56.01 Million | -1.49pp |
| 2004-12-31 | 7.29% | $2.74 Million | $37.64 Million | -43.28pp |
| 2002-12-31 | 50.57% | $10.65 Million | $21.06 Million | -13.91pp |
| 2001-12-31 | 64.48% | $12.94 Million | $20.07 Million | +5.71pp |
| 2000-12-31 | 58.77% | $11.59 Million | $19.72 Million | +4.79pp |
| 1999-12-31 | 53.97% | $2.50 Million | $4.63 Million | -0.38pp |
| 1998-12-31 | 54.35% | $2.50 Million | $4.60 Million | +11.61pp |
| 1997-12-31 | 42.74% | $5.00 Million | $11.70 Million | -36.21pp |
| 1996-12-31 | 78.95% | $1.50 Million | $1.90 Million | -- |
About Windtree Therapeutics Inc
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 sur… Read more